Research Roundup

OFFICIAL PUBLICATION OF

by its subsidiary APPco

Debbie Rigby 08/08/2017

Debbie Rigby rounds up the latest in research news Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease Analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial provides more evidence of the renoprotective effects of SGLT2 inhibitor empagliflozin in patients with type 2 diabetes and cardiovascular disease.

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

Teal questions pharmacist UTI programs

Indeed. I encounter a disheartening amount of surprised pikachu faces when I explain that I'll need to examine the eye…

James Lawson

Teal questions pharmacist UTI programs

At this point with how much the AMA/RACGP banged on about the "one male that was treated" during the Queensland…

Vincent Chua

Union calls for ‘significant’ increase to Award

Hospital pharmacists should consider community pharmacy as an alternative.

Ernie Hanson

Union calls for ‘significant’ increase to Award

"“ workplaces are characterised by high stress, understaffing and unsustainable workloads and with an expanded scope of practice on the…

James Tsaoucis

Research Roundup

Previous CWH: location rules "indefensible, nonsensical"

Next Weekly Dose: Methylprednisolone

In the beginning

The signs of ageing

Hyperpigmentation

How to avoid dry skin

MENU

Previous CWH: location rules "indefensible, nonsensical"

Next Weekly Dose: Methylprednisolone

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.